CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 16 enrolled
Drug / intervention
Tocilizumabbiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01741688
NCT01741688N/ACompleted
CompareCT.gov

A Multi-National, Multi-Center Non-Interventional Study in Rheumatoid Arthritis (RA) Patients Treated With Tocilizumab

Hoffmann-La Roche·observational·Posted Dec 5, 2012·Updated Aug 1, 2017

In Brief

An observational study evaluating Tocilizumab for Rheumatoid Arthritis. Completed, enrolled 16 participants across 4 sites.

Detailed Summary

This observational study evaluates the use and efficacy of intravenous (IV) tocilizumab in routine clinical practice in participants with moderate to severe rheumatoid arthritis. Eligible participants initiated on tocilizumab treatment in accordance with the local label were followed for 6 months.

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsRheumatoid Arthritis
CountriesPeru
Collaborators--

Timeline

N/ACompletedFinished
20132014201520162017201820192020202120222023202420252026
First PostedDec 5, 2012
Enrollment StartOct 26, 2012
Primary CompletionMar 6, 2014
TodayJul 2, 2026
Enrollment to primary: 1.4 yearsPosted 13.6 years ago

Interventions

Tocilizumabbiological

Tocilizumab was administered according to the local label.